Buch, Englisch, 146 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 3613 g
Reihe: Milestones in Drug Therapy
The First Once-daily Long-acting Beta2 Agonist for COPD
Buch, Englisch, 146 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 3613 g
Reihe: Milestones in Drug Therapy
ISBN: 978-3-0348-0708-1
Verlag: Springer
Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled ß2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Current Pharmacotherapy for COPD.- The preclinical pharmacology of indacaterol.- The design of the indacaterol molecule.- The early clinical development of Indacaterol.- INHANCE: An adaptive confirmatory study with dose selection at interim.- Phase III clinical efficacy studies – lung function.- Phase III Clinical Efficacy of Indacaterol.- Patient-centered Outcomes.- The history and performance of the Breezhaler device.- What does the future hold for the therapy of COPD?
